Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Pharmaust Limited (NUZ) Share Price & Analysis

NUZ Stock Chart & Stats

A$0.09A$0.00(0.00%)
At close: 4:00 PM GMT+11
AUD 0.06AUD 0.07AUD 0.08AUD 0.093 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
AUD 0.08 - AUD 0.09
52-Week Range
AUD 0.05 - AUD 0.12
Previous Close
AUD 0.09
Volume
246.69K
Average Volume (3M)
277.97K
Market Cap
AUD 68.08M
Enterprise Value
AUD 36.12M
Total Cash (Recent Filing)
AUD 12.71M
Total Debt (Recent Filing)
AUD 3.31M
Price to Earnings (P/E)
―
Beta
0.62
Next Earnings
Mar 03, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improved Equity Base

The substantial increase in equity provides a larger capitalization cushion than the company had in 2025. This may improve resilience against ongoing losses, support access to funding, and give management more flexibility while pursuing its biotechnology activities.

Narrower Net Loss

The reduction in annual net loss indicates some improvement in profitability relative to 2025, even though losses remain substantial. If maintained, this trend could reduce the pace of capital consumption and strengthen the company’s ability to progress development activities.

Reduced Cash Burn

A smaller absolute cash burn in 2026 is a constructive change because it suggests some improvement in cash discipline compared with the prior year. Continued reduction in outflows would extend financial runway and lessen the frequency or scale of future funding needs.

Bears Say

No Recent Revenue

The absence of reported revenue across three consecutive years leaves the company without demonstrated commercial income to support operations. This weakens self-funding capacity, increases dependence on external capital, and makes future financial performance reliant on achieving renewed commercialization.

Persistent Cash Burn

Sustained and very large operating cash outflows indicate that the business is not currently funding its activities from operations. Continued burn can consume the available capital cushion, require repeated financing, and constrain the company’s ability to invest without dilution or additional borrowing.

Renewed Debt And Losses

The return of debt alongside continuing negative returns on equity signals greater balance-sheet pressure despite improved capitalization. Borrowing adds repayment and financing obligations while losses persist, reducing flexibility and increasing the company’s exposure to future funding requirements.

Pharmaust Limited News

NUZ FAQ

What was Pharmaust Limited’s price range in the past 12 months?
Pharmaust Limited lowest share price was AU$0.05 and its highest was AU$0.12 in the past 12 months.
What is Pharmaust Limited’s market cap?
Pharmaust Limited’s market cap is AU$68.08M.
When is Pharmaust Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pharmaust Limited’s earnings last quarter?
Pharmaust Limited released its earnings results on Aug 27, 2026. The company reported -AU$0.007 earnings per share for the quarter.
Is Pharmaust Limited overvalued?
According to Wall Street analysts Pharmaust Limited’s price is currently Undervalued.
Does Pharmaust Limited pay dividends?
Pharmaust Limited does not currently pay dividends.
What is Pharmaust Limited’s EPS estimate?
Pharmaust Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmaust Limited have?
Pharmaust Limited has 791,652,340 shares outstanding.
What happened to Pharmaust Limited’s price movement after its last earnings report?
Pharmaust Limited reported an EPS of -AU$0.007 in its last earnings report. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of Pharmaust Limited?
Currently, no hedge funds are holding shares in AU:NUZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology